Non‐small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune‐related adverse events in first‐line treatments with immune checkpoint inhibitors: A retrospective single‐center study

BACKGROUND: Since 2015, immune checkpoint inhibitors have been a clinical treatment strategy for patients with advanced or recurrent non‐small cell lung cancer (NSCLC). However, the relationship between immune‐related adverse event (irAE) risk factors and patient clinical characteristics is unclear....

Descripción completa

Detalles Bibliográficos
Autores principales: Akazawa, Yuki, Yoshikawa, Aki, Kanazu, Masaki, Yano, Yukihiro, Yamaguchi, Toshihiko, Mori, Masahide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436681/
https://www.ncbi.nlm.nih.gov/pubmed/35820673
http://dx.doi.org/10.1111/1759-7714.14576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436681/
https://www.ncbi.nlm.nih.gov/pubmed/35820673
http://dx.doi.org/10.1111/1759-7714.14576

Ejemplares similares